Gout Therapy With Reduced Kidney Function
Keywords:
gout, kidney disease, febuxostat, allopurinol
Abstract
Gout is often combined with kidney disease. The pathology itself and concomitant hyperuricemia are considered as independent nephrotoxic factors. Urate-reducing therapy of gout can level the pathogenic effect of uric acid, preventing the development and progression of chronic kidney disease. However, in patients with reduced kidney function, its choice should be more careful. It is important to select not only the optimal urate-reducing drug, but also its dosing regimen. In this population, it is also difficult to set treatment goals and methods to evaluate its effectiveness. Xanthine oxidase inhibitors appear to be the most promising in the presence of renal pathology.
References
1. Roughley M., Sultan A.A., Clarson L. et al. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study // Arthritis Res. Ther. 2018. Vol. 20. № 1. P. 243.
2. Stack A.G., Johnson M.E., Blak B. et al. Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study // BMJ Open. 2019. Vol. 9. № 8. P. e031550.
3. Richette P., Doherty M., Pascual E. et al. 2016 updated EULAR evidence-based guidelines for the management of gout // Ann. Rheum. Dis. 2017. Vol. 76. № 1. P. 29- 42.
4. Finn W.F. Kidney disease and gout: the role of the innate immune system // The Open Urology & Nephrology Journal. 2016. Vol. 9. Suppl. 1: M3. P. 12.
5. Eliseev M.S. Algorithm of diagnostics and treatment of gout // RMJ. 2015. Т. 23. № 7. С. 410-415.
6. Johnson R.J., Bakris G.L., Borghi C. et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation // Am. J. Kidney Dis. 2018. Vol. 71. № 6. P. 851-865.
7. Zharikov S., Krotova K., Hu H. et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells // Am. J. Physiol. Cell. Physiol. 2008. Vol. 295. № 5. P. C1183-1190.
8. Roughley M.J., Belcher J., Mallen C.D. et al. Gout and risk of chronic kidney disease and nephrolithiasis: a meta-analysis of observational studies // Arthritis Res. Ther. 2015. Vol. 17. ID 90.
9. Mohammed E., Browne L.D., Kumar A.U. et al. Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: a national study // PLoS One. 2019. Vol. 14. № 1. P. e0210487.
10. Eliseev M.S. Chronic kidney disease: the role of hyperuricemia and opportunities for urate-reducing therapy // Modern Rheumatology. 2018. Т. 12. № 1. С. 60-65.
11. Thurston M.M., Phillips B.B., Bourg C.A. Safety and efficacy of allopurinol in chronic kidney disease // Ann. Pharmacother. 2013. Vol. 47. № 11. P. 1507-1516.
12. Pisano A., Cernaro V., Gembillo G. et al. Xanthine oxidase inhibitors for improving clinical function in chronic kidney disease patients: an updated systematic review and meta- analysis // Int. J. Mol. Sci. 2017. Vol. 18. № 11. P. E2283.
13. Ramasamy S.N., Korb-Wells C.S., Kannangara D.R.W. et al. Allopurinol hypersensitivity: a systematic review of all published cases 1950-2012 // Drug Safety. 2013. Vol. 36. № 10. P. 953- 980.
14. Vargas-Santos A.B., Peloquin C.E., Zhang Y., Neogi T. Association of chronic kidney disease with allopurinol use in gout treatment // JAMA Intern. Med. 2018. Vol. 178. № 11. P. 1526-1533.
15. Golmohammadi S., Almasi A., Manouchehri M. et al. Allopurinol against progression of chronic kidney disease // Iran J. Kidney Dis. 2017. Vol. 11. № 4. P. 286-293.
16. Kamel B., Graham G.G., Williams K.M. et al. Clinical pharmacokinetics and pharmacodynamics of febuxostat // Clin. Pharmacokinet. 2017. Vol. 56. № 5. P. 459-475.
17. Chou H.W., Chiu H.T., Tsai C.W. et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study // Nephrol. Dial. Transplant. 2018. Vol. 33. № 9. P. 1620-1627.
18. Lee J.W., Lee K.H.. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease // Int. Urol. Nephrol. 2019. Vol. 51. № 3. P. 467-473.
19. Lin T.C., Hung L.Y., Chen Y.C. et al. Effects of febuxostat on renal function in patients with chronic kidney disease: a systematic review and meta-analysis // Medicine (Baltimore). 2019. Vol. 98. № 29. P. e16311.
20. Whelton A., MacDonald P.A., Chefo S., Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study // Postgrad. Med. 2013. Vol. 125. № 1. P. 106-114.
21. Liu X., Wang H., Ma R. et al. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5 // Clin. Exp. Nephrol. 2019. Vol. 23. № 3. P. 362-370.
22. Schumacher H.R.Jr., Becker M.A., Wortmann R.L. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28- week, phase III, randomized, double-blind, parallel-group trial // Arthritis Rheum. 2008. Vol. 59. № 11. P. 1540-1548.
23. Zhang X., Wan D., Yang G. et al. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia // Int. Urol. Nephrol. 2019. Vol. 51. № 12. P. 2273-2283.
2. Stack A.G., Johnson M.E., Blak B. et al. Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study // BMJ Open. 2019. Vol. 9. № 8. P. e031550.
3. Richette P., Doherty M., Pascual E. et al. 2016 updated EULAR evidence-based guidelines for the management of gout // Ann. Rheum. Dis. 2017. Vol. 76. № 1. P. 29- 42.
4. Finn W.F. Kidney disease and gout: the role of the innate immune system // The Open Urology & Nephrology Journal. 2016. Vol. 9. Suppl. 1: M3. P. 12.
5. Eliseev M.S. Algorithm of diagnostics and treatment of gout // RMJ. 2015. Т. 23. № 7. С. 410-415.
6. Johnson R.J., Bakris G.L., Borghi C. et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation // Am. J. Kidney Dis. 2018. Vol. 71. № 6. P. 851-865.
7. Zharikov S., Krotova K., Hu H. et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells // Am. J. Physiol. Cell. Physiol. 2008. Vol. 295. № 5. P. C1183-1190.
8. Roughley M.J., Belcher J., Mallen C.D. et al. Gout and risk of chronic kidney disease and nephrolithiasis: a meta-analysis of observational studies // Arthritis Res. Ther. 2015. Vol. 17. ID 90.
9. Mohammed E., Browne L.D., Kumar A.U. et al. Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: a national study // PLoS One. 2019. Vol. 14. № 1. P. e0210487.
10. Eliseev M.S. Chronic kidney disease: the role of hyperuricemia and opportunities for urate-reducing therapy // Modern Rheumatology. 2018. Т. 12. № 1. С. 60-65.
11. Thurston M.M., Phillips B.B., Bourg C.A. Safety and efficacy of allopurinol in chronic kidney disease // Ann. Pharmacother. 2013. Vol. 47. № 11. P. 1507-1516.
12. Pisano A., Cernaro V., Gembillo G. et al. Xanthine oxidase inhibitors for improving clinical function in chronic kidney disease patients: an updated systematic review and meta- analysis // Int. J. Mol. Sci. 2017. Vol. 18. № 11. P. E2283.
13. Ramasamy S.N., Korb-Wells C.S., Kannangara D.R.W. et al. Allopurinol hypersensitivity: a systematic review of all published cases 1950-2012 // Drug Safety. 2013. Vol. 36. № 10. P. 953- 980.
14. Vargas-Santos A.B., Peloquin C.E., Zhang Y., Neogi T. Association of chronic kidney disease with allopurinol use in gout treatment // JAMA Intern. Med. 2018. Vol. 178. № 11. P. 1526-1533.
15. Golmohammadi S., Almasi A., Manouchehri M. et al. Allopurinol against progression of chronic kidney disease // Iran J. Kidney Dis. 2017. Vol. 11. № 4. P. 286-293.
16. Kamel B., Graham G.G., Williams K.M. et al. Clinical pharmacokinetics and pharmacodynamics of febuxostat // Clin. Pharmacokinet. 2017. Vol. 56. № 5. P. 459-475.
17. Chou H.W., Chiu H.T., Tsai C.W. et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study // Nephrol. Dial. Transplant. 2018. Vol. 33. № 9. P. 1620-1627.
18. Lee J.W., Lee K.H.. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease // Int. Urol. Nephrol. 2019. Vol. 51. № 3. P. 467-473.
19. Lin T.C., Hung L.Y., Chen Y.C. et al. Effects of febuxostat on renal function in patients with chronic kidney disease: a systematic review and meta-analysis // Medicine (Baltimore). 2019. Vol. 98. № 29. P. e16311.
20. Whelton A., MacDonald P.A., Chefo S., Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study // Postgrad. Med. 2013. Vol. 125. № 1. P. 106-114.
21. Liu X., Wang H., Ma R. et al. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5 // Clin. Exp. Nephrol. 2019. Vol. 23. № 3. P. 362-370.
22. Schumacher H.R.Jr., Becker M.A., Wortmann R.L. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28- week, phase III, randomized, double-blind, parallel-group trial // Arthritis Rheum. 2008. Vol. 59. № 11. P. 1540-1548.
23. Zhang X., Wan D., Yang G. et al. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia // Int. Urol. Nephrol. 2019. Vol. 51. № 12. P. 2273-2283.
Published
2022-11-25
How to Cite
Fayzullaevna, M. G., Otakhanovich, J. O., Tokhirovna, B. N., Mamatovich, R. A., & Bakhadirovich, J. S. (2022). Gout Therapy With Reduced Kidney Function. Central Asian Journal of Medical and Natural Science, 3(6), 198 - 203. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/1194
Section
Articles
